Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience (NAGE)
NASDAQ:NAGE
Total Valuation
Niagen Bioscience has a market cap or net worth of $678.76M. The enterprise value is $391.31M.
Market Cap$678.76M
Enterprise Value$391.31M
Share Statistics
Niagen Bioscience has 77,750,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,750,450
Owned by Insiders29.93%
Owned by Institutions0.15%
Financial Efficiency
Niagen Bioscience’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 14.53%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)14.53%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee957.66K
Profits Per Employee82.21K
Employee Count104
Asset Turnover1.46
Inventory Turnover4.14
Valuation Ratios
The current PE Ratio of Niagen Bioscience is 53.05. Niagen Bioscience’s PEG ratio is -0.22.
PE Ratio53.05
PS Ratio0.00
PB Ratio9.84
Price to Fair Value9.84
Price to FCF37.97
Price to Operating Cash Flow37.46
PEG Ratio-0.22
Income Statement
In the last 12 months, Niagen Bioscience had revenue of 99.60M and earned 8.55M in profits. Earnings per share was 0.10.
Revenue99.60M
Gross Profit61.59M
Operating Income7.73M
Pretax Income8.86M
Net Income8.55M
EBITDA9.21M
Earnings Per Share (EPS)0.10
Cash Flow
In the last 12 months, operating cash flow was 12.11M and capital expenditures -163.00K, giving a free cash flow of 11.95M billion.
Operating Cash Flow12.11M
Free Cash Flow11.95M
Free Cash Flow per Share0.15
Dividends & Yields
Niagen Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change120.63%
50-Day Moving Average7.09
200-Day Moving Average5.36
Relative Strength Index (RSI)65.92
Average Volume (3m)708.63K
Important Dates
Niagen Bioscience upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Niagen Bioscience as a current ratio of 3.57, with Debt / Equity ratio of 5.75%
Current Ratio3.57
Quick Ratio3.06
Debt to Market Cap0.00
Net Debt to EBITDA-4.54
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Niagen Bioscience has paid 305.00K in taxes.
Income Tax305.00K
Effective Tax Rate0.03
Enterprise Valuation
Niagen Bioscience EV to EBITDA ratio is 44.71, with an EV/FCF ratio of 34.47.
EV to Sales4.13
EV to EBITDA44.71
EV to Free Cash Flow34.47
EV to Operating Cash Flow34.00
Balance Sheet
Niagen Bioscience has $44.51M in cash and marketable securities with $328.77K in debt, giving a net cash position of -$41.86M billion.
Cash & Marketable Securities$44.51M
Total Debt$328.77K
Net Cash-$41.86M
Net Cash Per Share-$0.54
Tangible Book Value Per Share$0.54
Margins
Gross margin is 61.84%, with operating margin of 7.76%, and net profit margin of 8.58%.
Gross Margin61.84%
Operating Margin7.76%
Pretax Margin8.89%
Net Profit Margin8.58%
EBITDA Margin9.25%
EBIT Margin7.76%
Analyst Forecast
The average price target for Niagen Bioscience is $9.03, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.03
Price Target Upside6.86% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast19.18%
EPS Growth Forecast―